---
document_datetime: 2023-09-21 19:24:30
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/raplixa-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: raplixa-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.6513433
conversion_datetime: 2025-12-26 11:19:58.673454
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Raplixa

<!-- image -->

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on no   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|------------------------------------------------|----------------------------------|-----------|
| IAIN/0022            | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP product | 12/04/2017                          | n/a                                            |                                  |           |
| IB/0021/G            | This was an application for a group of variations.                                                                                                                                                                                                     | 06/04/2017                          |                                                | SmPC                             |           |

<!-- image -->

<!-- image -->

Medicinal product no longer authorised

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) B.II.f.1.e - Stability of FP - Change to an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | authorised    |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|
| IA/0020/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the Medicinal product | 13/03/2017 no |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier   |                    |                                   |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|-----------------------------------|-----------------------------------|
| IAIN/0018           | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP            | 24/01/2017         | n/a                               | authorised                        |
| PSUSA/10297 /201606 | Periodic Safety Update EU Single assessment - human fibrinogen / human thrombin                                                                                                                                                                           | 12/01/2017         | n/a longer                        | PRAC Recommendation - maintenance |
| T/0017              | Transfer of Marketing Authorisation                                                                                                                                                                                                                       | 29/11/2016 no      | 23/12/2016 SmPC, Labelling and PL |                                   |
| IB/0016             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                            | 01/11/2016 product | 23/12/2016 SmPC, Labelling and PL |                                   |
| IB/0014             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data Medicinal                                                                          | 12/08/2016         | n/a                               |                                   |
| IAIN/0013           | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP            | 14/07/2016         | n/a                               |                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| PSUSA/10297 /201512   | Periodic Safety Update EU Single assessment - human fibrinogen / human thrombin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 07/07/2016   | n/a           | PRAC Recommendation               |
|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|-----------------------------------|
| IAIN/0012             | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 25/04/2016   | 24/10/2016    | SmPC, Labelling and PL authorised |
| II/0010/G             | This was an application for a group of variations. B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test B.I.d.1.a.1 - Stability of AS - Change in the re-test                                                                                                                                     | 14/04/2016   | n/a no longer |                                   |
| II/0009/G             | period/storage period - Reduction This was an application for a group of variations. B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including Medicinal product | 25/02/2016   | n/a           |                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | replacement or addition) B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |               |                               |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|-------------------------------|
| PSUSA/10297 /201506 | Periodic Safety Update EU Single assessment - human fibrinogen / human thrombin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 14/01/2016 | n/a           |                               |
| IB/0007/G           | This was an application for a group of variations. B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting product | 17/12/2015 | n/a no longer | material/intermediate/reagent |
| IB/0008             | - Other variation B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 10/11/2015 | 24/10/2016    |                               |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IA/0005   | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                             | 01/09/2015    | n/a            |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|----------------|
| IB/0004   | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                          | 24/08/2015    | n/a authorised |
| IB/0003/G | This was an application for a group of variations. B.II.b.5.f - Change to in-process tests or limits applied during the manufacture of the finished product - Addition or replacement of an in-process test as a result of a safety or quality issue B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including | 12/08/2015 no | n/a longer     |
| IAIN/0002 | replacement or addition) B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP product                                                                                                                                                                                                 | 16/07/2015    | n/a            |
| IAIN/0001 | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP Medicinal                                                                                                                                                                                                                        | 16/07/2015    | n/a            |